196 related articles for article (PubMed ID: 30765167)
21. Inactivated infectious haematopoietic necrosis virus (IHNV) vaccines.
Anderson E; Clouthier S; Shewmaker W; Weighall A; LaPatra S
J Fish Dis; 2008 Oct; 31(10):729-45. PubMed ID: 18752542
[TBL] [Abstract][Full Text] [Related]
22. Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-α-dependent apoptosis.
Ato M; Takahashi Y; Fujii H; Hashimoto S; Kaji T; Itamura S; Horiuchi Y; Arakawa Y; Tashiro M; Takemori T
Vaccine; 2013 Apr; 31(17):2184-90. PubMed ID: 23434386
[TBL] [Abstract][Full Text] [Related]
23. Assessments of different inactivating reagents in formulating transmissible gastroenteritis virus vaccine.
Zhao F; Liu L; Xu M; Shu X; Zheng L; Wei Z
Virol J; 2020 Oct; 17(1):163. PubMed ID: 33097081
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004.
Mitchell DK; Ruben FL; Gravenstein S
Pediatr Infect Dis J; 2005 Oct; 24(10):925-7. PubMed ID: 16220095
[TBL] [Abstract][Full Text] [Related]
25. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
Brett IC; Johansson BE
Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a human H9N2 influenza virus isolated in Hong Kong.
Saito T; Lim W; Suzuki T; Suzuki Y; Kida H; Nishimura SI; Tashiro M
Vaccine; 2001 Oct; 20(1-2):125-33. PubMed ID: 11567756
[TBL] [Abstract][Full Text] [Related]
27. Comparative safety, immunogenicity, and efficacy of several anti-H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine).
Gambaryan AS; Lomakina NF; Boravleva EY; Kropotkina EA; Mashin VV; Krasilnikov IV; Klimov AI; Rudenko LG
Influenza Other Respir Viruses; 2012 May; 6(3):188-95. PubMed ID: 21951678
[TBL] [Abstract][Full Text] [Related]
28. Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity.
Raviv Y; Blumenthal R; Tompkins SM; Humberd J; Hogan RJ; Viard M
J Virol; 2008 May; 82(9):4612-9. PubMed ID: 18305038
[TBL] [Abstract][Full Text] [Related]
29. The stability and immunogenicity of inactivated MDCK cell-derived influenza H7N9 viruses.
Tzeng TT; Lai CC; Weng TC; Cyue MH; Tsai SY; Tseng YF; Sung WC; Lee MS; Hu AY
Vaccine; 2019 Nov; 37(47):7117-7122. PubMed ID: 31383484
[TBL] [Abstract][Full Text] [Related]
30. IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.
Terauchi Y; Sano K; Ainai A; Saito S; Taga Y; Ogawa-Goto K; Tamura SI; Odagiri T; Tashiro M; Fujieda M; Suzuki T; Hasegawa H
Hum Vaccin Immunother; 2018 Jun; 14(6):1351-1361. PubMed ID: 29425074
[TBL] [Abstract][Full Text] [Related]
31. Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes.
Kon TC; Onu A; Berbecila L; Lupulescu E; Ghiorgisor A; Kersten GF; Cui YQ; Amorij JP; Van der Pol L
PLoS One; 2016; 11(3):e0150700. PubMed ID: 26959983
[TBL] [Abstract][Full Text] [Related]
32. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.
Khurana S; Coyle EM; Verma S; King LR; Manischewitz J; Crevar CJ; Carter DM; Ross TM; Golding H
Vaccine; 2014 Nov; 32(48):6421-32. PubMed ID: 25284811
[TBL] [Abstract][Full Text] [Related]
33. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
34. Principles of selective inactivation of viral genome. VIII. The influence of beta-propiolactone on immunogenic and protective activities of influenza virus.
Budowsky EI; Smirnov YuA ; Shenderovich SF
Vaccine; 1993; 11(3):343-8. PubMed ID: 8447162
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of inactivated H5N2 influenza vaccines against lethal A/Chicken/Queretaro/19/95 infection.
Garcia A; Johnson H; Srivastava DK; Jayawardene DA; Wehr DR; Webster RG
Avian Dis; 1998; 42(2):248-56. PubMed ID: 9645315
[TBL] [Abstract][Full Text] [Related]
36. An Adenovirus-Vectored Influenza Vaccine Induces Durable Cross-Protective Hemagglutinin Stalk Antibody Responses in Mice.
Kim EH; Han GY; Nguyen H
Viruses; 2017 Aug; 9(8):. PubMed ID: 28825679
[TBL] [Abstract][Full Text] [Related]
37. Selective Capture and Determination of Receptor-Binding Hemagglutinin in Influenza Vaccine Preparations Using a Coupled Receptor-Binding/RP-HPLC Assay.
Lorbetskie B; Cunningham AM; Lemieux M; Durno L; Farnsworth A; Wang J; Li C; Li X; Gilbert M; Sauvé S; Girard M
Anal Chem; 2019 Jul; 91(14):8908-8917. PubMed ID: 31251585
[TBL] [Abstract][Full Text] [Related]
38. How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines.
Rudraraju R; Mordant F; Subbarao K
J Infect Dis; 2019 Apr; 219(Suppl_1):S81-S87. PubMed ID: 30715386
[No Abstract] [Full Text] [Related]
39. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs.
Katz JM; Webster RG
J Infect Dis; 1989 Aug; 160(2):191-8. PubMed ID: 2760480
[TBL] [Abstract][Full Text] [Related]
40. Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral Capsids.
Fan C; Ye X; Ku Z; Kong L; Liu Q; Xu C; Cong Y; Huang Z
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
